| Universal Therapy Group Llc | |
|
2750 Mount Pleasant St, Suite 104, Burlington, IA 52601-2136 | |
| (319) 750-1911 | |
| Not Available |
| Full Name | Universal Therapy Group Llc |
|---|---|
| Type | Facility |
| Speciality | Occupational Therapist |
| Location | 2750 Mount Pleasant St, Burlington, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902190259 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 001894 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Universal Therapy Group Llc 2750 Mount Pleasant St, Suite 104, Burlington, IA 52601-2136 Ph: () - | Universal Therapy Group Llc 2750 Mount Pleasant St, Suite 104, Burlington, IA 52601-2136 Ph: (319) 750-1911 |
News Archive
Rapid evolution of a protein produced by an immunity gene is associated with increased antiviral activity in humans, a finding that suggests evolutionary biology and virology together can accelerate the discovery of viral-defense mechanisms, according to researchers at Fred Hutchinson Cancer Research Center.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel "lipidoid" formulations for the systemic delivery of RNAi therapeutics.
Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.
The Biden administration announced plans Wednesday to offer boosters to all U.S. adults as soon as next month, saying that recent data, including some made available only in the past few days, played a role in that decision.
› Verified 3 days ago
Christina Marie Scott, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1212 Indian Hills Dr, Burlington, IA 52601 Phone: 319-752-4100 | |
Cinnamon L Spear, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2750 Mount Pleasant St Ste 104, Burlington, IA 52601 Phone: 319-750-1911 |